Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Oct. 4, 2013 -- Stelara, an injectable drug already approved to treat psoriasis, is now also approved to treat psoriatic arthritis. Psoriatic arthritis is an autoimmune disease. The immune system ...

Toronto, ON, (January 14, 2010) -Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

Samsung Bioepis, a biosimilar drug developer under Samsung Group, said Tuesday it has received approval to sell its ...

A recent study from the University of North Carolina at Chapel Hill revealed specialty drug costs for payers have tripled since 2003, when they represented 11 percent of payer drug spending. 1.

Samsung Bioepis’ ustekinumab biosimilar receives Japanese marketing approval: Incheon, Korea Wednesday, December 24, 2025, 15:00 Hrs [IST] Samsung Bioepis Co., Ltd., a biopharma ...